stockportfolio.pro
Sutro Biopharma, Inc. (STRO)
Healthcare · Biotechnology · NasdaqGM
Sutro Biopharma, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.73M | $51.74M | $38.42M | $42.74M | $42.72M | $61.88M | $67.77M | $153.73M | $62.04M | $102.48M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $1.70M | $-19.69M | $-35.32M | $-119.20M | $-32.13M | $-105.54M | $-119.20M | $-106.79M | $-227.46M | $-191.09M |
| Net margin | 2.8% | -38.1% | -91.9% | -278.9% | -75.2% | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
Source: Sutro Biopharma, Inc. SEC filings (10-K).
Explore 10 years of Sutro Biopharma, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track STRO in your portfolio →
Sutro Biopharma, Inc. financial history by metric
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma, Inc. — frequently asked questions
What is Sutro Biopharma, Inc.'s revenue?
Sutro Biopharma, Inc. (STRO) reported revenue of $102.48M for fiscal year 2025, up 65.2% from the prior year, according to its SEC filings.
Is Sutro Biopharma, Inc. profitable?
No — STRO reported a net loss of $-191.09M in fiscal 2025.
What is STRO's P/E ratio?
Sutro Biopharma, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Sutro Biopharma, Inc. growing?
STRO's revenue grew at roughly 19.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Sutro Biopharma, Inc. have?
As of fiscal year 2025, STRO carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Sutro Biopharma, Inc.'s market cap?
Sutro Biopharma, Inc. (STRO) has a market capitalization of about $446.74M, based on the latest data in our nightly-refreshed cache.
When does Sutro Biopharma, Inc.'s fiscal year end?
STRO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Sutro Biopharma, Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.